08:00 , Nov 3, 2014 |  BioCentury  |  Finance

Metallic strategy

Viamet Pharmaceuticals Inc. 's decision to do a $60 million series D round one day after withdrawing its planned $75 million IPO late last month can be explained by a "choppy" IPO market and a...
07:00 , Apr 28, 2014 |  BioCentury  |  Strategy

GSK's special feeling

Nearly 15 years after Glaxo Wellcome plc and SmithKline Beecham plc merged to form the world's largest drug company, GlaxoSmithKline plc is steadily downsizing to focus on areas like vaccines and respiratory diseases where it...
07:00 , Apr 14, 2014 |  BioCentury  |  Product Development

Unlocking cancer data

By Erin McCallister  The industry organizers of Project Data Sphere LLC expect their cancer data-sharing initiative will get to scale faster than similar initiatives led by academics and not-for-profits in other diseases because it has...
07:00 , Jul 1, 2013 |  BC Week In Review  |  Company News

GlaxoSmithKline, Pfizer, Agency for Science, Technology and Research (A*STAR), Siemens deal

A*STAR launched an R&D consortium to increase productivity in Singapore by offering next-generation manufacturing technologies to the pharma and specialty chemicals industries. The Innovative Processing of Specialties and Pharmaceuticals (iPSP) consortium will also provide a...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Glaxo Wellcome other research news

Glaxo will form a Genetics Directorate for research and development with a budget of £30 million ($49.2 million) for 1997. The Directorate is comprised of 150 researchers at facilities in Stevenage, U.K., Research Triangle Park,...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

IGT preclinical data

IGT reported results of studies in a mouse model of cervical cancer that compared AVLB with a similar drug, Navelbine , produced by Glaxo Wellcome. Separate groups of mice were given 20 mg/kg doses of...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Glaxo Wellcome Research and Development S.A. other research news

Researchers reported the isolation of a chemokine blocker from the herpesvirus that is suspected as the causative agent in KS. The blocker is broadly active, binding to many chemokine receptors and preventing infection by many...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Oxford Molecular other research news

A European consortium led by OMG received a £450,000 (US$756,000) Eureka grant from the U.K. Department of Trade and Industry to develop a library of software that will be delivered without charge on the Internet....
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

MDL Information Systems Inc., Glaxo Wellcome deal

Glaxo will pay MDLI several million dollars over three years for chemical and biological information management and scientific databases that can be customized to the specific research workflow of Glaxo’s global research operations MDL Information...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Glaxo Wellcome management update

Glaxo Wellcome plc, London, U.K.   Business: Drug discovery   Hired: Allen Roses, M.D., as VP and director of the pharma company's Genetics Directorate (see B14) while remaining adjunct professor of neurobiology and neurology at...